Products You May Like
SANTA FE, N.M., June 17, 2021 (GLOBE NEWSWIRE) — Avisa Diagnostics Inc. (CSE: AVBT) (Avisa), a clinical-stage medical gadget firm growing an ultra-rapid, point-of-care biomarker breath check for the detection and monitoring of bacterial load in post-COVID-19 lengthy haulers and for ventilator-associated pneumonia, introduced right this moment that the Firm will take part in Renmark Monetary Communications Inc.’s stay Digital Non-Deal Roadshow Sequence on June 17, 2021 at 12:00 PM ET.
Avisa Diagnostics’ President and CEO, David S. Joseph, will give an organization presentation, adopted by a stay Q&A session. Buyers all for collaborating on this occasion might want to register utilizing the hyperlink beneath. Registration for the stay occasion could also be restricted, however entry to a replay after the stay occasion shall be obtainable on the Firm’s web site (www.avisadx.com) within the Buyers part.
REGISTER HERE: https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-cse-avbt-2021-06-17-120000
To make sure easy connectivity, please entry this hyperlink utilizing the most recent model of Google Chrome.
About Renmark Monetary Communications Inc.
Based in 1999, Renmark Monetary Communications Inc. is North America’s main retail investor relations agency. Using a strategic and complete mixture of publicity ways; Renmark hosts Digital Non-Deal Roadshows in addition to in-person company displays and maintains day by day communications with 1000’s of brokers and cash managers throughout Canada and the US. Renmark empowers its publicly-traded clientele to maximise their visibility inside the monetary group and strengthen their investor viewers. For extra details about Renmark and its occasions, please contact Scott Logan at slogan@renmarkfinancial.com, +1 (416) 644-2020 or +1 (514) 939-3989.
About Avisa Diagnostics Inc.
Avisa (CSE-AVBT) is a clinical-stage medical gadget firm growing the Avisa BreathTest™, a novel drug/gadget biomarker know-how platform that allows the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the affected person inhales or ingests its proprietary drug substrates. The Firm has established scientific proof-of-concept by trials in cystic fibrosis, tuberculosis and community-acquired pneumonia, which demonstrated constructive security and scientific efficacy outcomes. Avisa is planning pivotal trials in Submit-COVID-19 bronchiectasis and ventilator-associated pneumonia and plans to submit Investigational Machine Exemption functions to the U.S. FDA for these trials subsequent yr. For additional data, go to https://avisadx.com/ and observe us on LinkedIn and Twitter.
Contact
Avisa Diagnostics Inc.
David S. Joseph
President and Chief Government Officer
Telephone: +1 610 947 0360
E-mail: info@avisadx.com
www.avisadx.com
Buyers and Media Contacts
MC Providers AG
Laurie Doyle, Raimund Gabriel
E-mail: avisa@mc-services.eu
Europe: +49 89-210 2280
U.S.: +1-339-832-0752
Ahead-looking Statements
This press launch accommodates statements which represent “forward-looking data” inside the which means of relevant securities legal guidelines, together with statements relating to the plans, intentions, beliefs and present expectations of the Firm with respect to future enterprise actions and working efficiency. Ahead-looking data is usually recognized by the phrases “might”, “would”, “may”, “ought to”, “will”, “intend”, “plan”, “anticipate”, “imagine”, “estimate”, “anticipate” or related expressions and contains, however is just not restricted to, statements concerning the enterprise plans and expectations of the Firm and expectations for different financial, enterprise, and/or aggressive elements. Buyers are cautioned that forward- trying data is just not primarily based on historic details however as a substitute displays the Firm’s administration’s expectations, estimates or projections regarding future outcomes or occasions primarily based on the opinions, assumptions and estimates of administration thought of affordable on the date the statements are made. Though the Firm believes that the expectations mirrored in such forward-looking data are affordable, such data includes dangers and uncertainties, and undue reliance shouldn’t be positioned on such data, as unknown or unpredictable elements may have materials antagonistic results on future outcomes, efficiency or achievements of the Ensuing Issuer. Among the many key elements that might trigger precise outcomes to vary materially from these projected within the forward-looking data are the next: (i) modifications usually financial, enterprise and political situations, together with modifications within the monetary markets, modifications in relevant legal guidelines and rules each regionally and in overseas jurisdictions; (ii) compliance with intensive authorities regulation and the prices related to compliance; (iii) the dangers and uncertainties related to overseas markets; and (iv) dangers related to the COVID-19 pandemic. This forward-looking data could also be affected by dangers and uncertainties within the enterprise of the Ensuing Issuer and market situations. Ought to a number of of those dangers or uncertainties materialize, or ought to assumptions underlying the forward-looking data show incorrect, precise outcomes might range materially from these described herein as supposed, deliberate, anticipated, believed, estimated or anticipated. Though the Firm has tried to establish necessary dangers, uncertainties and elements which may trigger precise outcomes to vary materially, there could also be others that trigger outcomes to not be as anticipated, estimated or supposed and such modifications could possibly be materials. The Firm doesn’t intend, nor assume any obligation, to replace this forward-looking data besides as in any other case required by relevant legislation.
Neither the CSE nor its Market Regulator (as that time period is outlined within the insurance policies of the CSE) accepts duty for the adequacy or accuracy of this launch.
